Pfizer Chairman and CEO Albert Bourla explores the strategic evolution of the pharmaceutical industry, emphasizing a shift toward pure-play innovative medicine over diversified consumer healthcare. Following the rapid development of the COVID-19 vaccine, the company is prioritizing the obesity market through the acquisition of Metsera, betting on the potential of monthly injectable treatments to surpass current weekly alternatives. A significant competitive threat is emerging from China, where massive investment in R&D and academic excellence has enabled Chinese firms to develop medicines at half the cost and triple the speed of Western counterparts. To maintain global leadership against this "different league" of productivity, Pfizer is undergoing a technological transformation centered on artificial intelligence. This integration of AI aims to fundamentally redesign drug discovery and manufacturing processes, matching the unprecedented speed and efficiency required to compete in the next decade of global biotechnology.
Sign in to continue reading, translating and more.
Open full episode in Podwise